The historical rank and industry rank for AbCellera Biologics's OCF Margin % or its related term are showing as below:
STU:8QQ'
s OCF Margin % Range Over the Past 10 Years
Min: -376.5 Med: 16.47 Max: 65.19
Current: -193.66
During the past 8 years, the highest OCF Margin % of AbCellera Biologics was 65.19%. The lowest was -376.50%. And the median was 16.47%.
STU:8QQ's OCF Margin % is ranked worse than 61.25% of 960
companies
in the Biotechnology industry
Industry Median: -68.59
vs STU:8QQ: -193.66
AbCellera Biologics OCF Margin % Related Terms
AbCellera Biologics OCF Margin % Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:8QQ vs SRPT, RAPP, RXRX: OCF Margin % Comparison
For the Biotechnology subindustry, AbCellera Biologics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (STU:8QQ) has a OCF Margin % of -403.18% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #588 out of 960 companies in the Biotechnology industry, placing it in the top 61.2%.
Is AbCellera Biologics' OCF Margin % too high?
AbCellera Biologics' current OCF Margin % is -403.18%. Based on the distribution chart, AbCellera Biologics ranks #588 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' OCF Margin % compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #588 out of 960 companies for OCF Margin %. This places AbCellera Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current OCF Margin % is -403.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (STU:8QQ) is currently considered Fairly Valued. The stock's GF Value™ is €4.92, compared to a current price of €5.27 — trading 7.1% above its estimated fair value. The current OCF Margin % is -403.18%. AbCellera Biologics' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For AbCellera Biologics (STU:8QQ), the current OCF Margin % is -403.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (STU:8QQ) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of €5.27 is trading 7.1% above its estimated GF Value™ of €4.92.
GuruFocus considers AbCellera Biologics to be Fairly Valued.
Key valuation signals for STU:8QQ:
OCF Margin %: -403.18%
GF Value™: €4.92 vs. price of €5.27 (7.1% above fair value)
No single metric tells the full story. See the STU:8QQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
60GF Score
Get the complete analysis for STU:8QQ
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8QQ has been successfully added to your 
